HIP
REGN icon

Harrell Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Harrell Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
2,089
+27
+1% +$18.4K 0.28% 69
2026
Q1 		$1.59M Sell
2,062
-16
-0.8% -$12.2K 0.38% 62
2025
Q4 		$1.6M Sell
2,078
-2
-0.1% -$1.36K 0.38% 61
2025
Q3 		$1.17M Buy
2,080
+70
+3% +$39.6K 0.28% 63
2025
Q2 		$1.06M Buy
+2,010
New +$1.12M 0.27% 63

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Harrell Investment Partners's REGN Position: Q2 2026 in Review

Harrell Investment Partners increased its Regeneron Pharmaceuticals (REGN) stake by 1.3% in Q2 2026, buying an estimated $18.4K and bringing the position to 2,089 shares worth $1.3M. The position accounts for 0.28% of the portfolio, ranked #69.

Harrell Investment Partners first reported a position in REGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.6M in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Harrell Investment Partners held 2,089 shares of Regeneron Pharmaceuticals worth $1.3M as of Q2 2026.
  • Harrell Investment Partners bought 27 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $18.4K.
  • Regeneron Pharmaceuticals made up 0.28% of Harrell Investment Partners's portfolio in Q2 2026, its #69 holding.
  • Harrell Investment Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Harrell Investment Partners's Regeneron Pharmaceuticals position peaked at $1.6M in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Harrell Investment Partners's 13F filing for Q2 2026, filed 9 Jul 2026.